327 related articles for article (PubMed ID: 32807895)
1. An integrated drug repurposing strategy for the rapid identification of potential SARS-CoV-2 viral inhibitors.
Trezza A; Iovinelli D; Santucci A; Prischi F; Spiga O
Sci Rep; 2020 Aug; 10(1):13866. PubMed ID: 32807895
[TBL] [Abstract][Full Text] [Related]
2. Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using
Choudhary S; Malik YS; Tomar S
Front Immunol; 2020; 11():1664. PubMed ID: 32754161
[TBL] [Abstract][Full Text] [Related]
3. A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor.
Souza PFN; Lopes FES; Amaral JL; Freitas CDT; Oliveira JTA
Int J Biol Macromol; 2020 Dec; 164():66-76. PubMed ID: 32693122
[TBL] [Abstract][Full Text] [Related]
4.
Br B; Damle H; Ganju S; Damle L
F1000Res; 2020; 9():663. PubMed ID: 32765844
[No Abstract] [Full Text] [Related]
5. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions.
Day CJ; Bailly B; Guillon P; Dirr L; Jen FE; Spillings BL; Mak J; von Itzstein M; Haselhorst T; Jennings MP
mBio; 2021 Mar; 12(2):. PubMed ID: 33785634
[TBL] [Abstract][Full Text] [Related]
6. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
Fantini J; Chahinian H; Yahi N
Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32405156
[TBL] [Abstract][Full Text] [Related]
7. Dynamics of the ACE2-SARS-CoV-2/SARS-CoV spike protein interface reveal unique mechanisms.
Ali A; Vijayan R
Sci Rep; 2020 Aug; 10(1):14214. PubMed ID: 32848162
[TBL] [Abstract][Full Text] [Related]
8. Computational Alanine Scanning and Structural Analysis of the SARS-CoV-2 Spike Protein/Angiotensin-Converting Enzyme 2 Complex.
Laurini E; Marson D; Aulic S; Fermeglia M; Pricl S
ACS Nano; 2020 Sep; 14(9):11821-11830. PubMed ID: 32833435
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 (COVID-19) structural and evolutionary dynamicome: Insights into functional evolution and human genomics.
Gupta R; Charron J; Stenger CL; Painter J; Steward H; Cook TW; Faber W; Frisch A; Lind E; Bauss J; Li X; Sirpilla O; Soehnlen X; Underwood A; Hinds D; Morris M; Lamb N; Carcillo JA; Bupp C; Uhal BD; Rajasekaran S; Prokop JW
J Biol Chem; 2020 Aug; 295(33):11742-11753. PubMed ID: 32587094
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Binding to ACE2 Receptors from Human, Pets, Farm Animals, and Putative Intermediate Hosts.
Zhai X; Sun J; Yan Z; Zhang J; Zhao J; Zhao Z; Gao Q; He WT; Veit M; Su S
J Virol; 2020 Jul; 94(15):. PubMed ID: 32404529
[TBL] [Abstract][Full Text] [Related]
11. Coevolution, Dynamics and Allostery Conspire in Shaping Cooperative Binding and Signal Transmission of the SARS-CoV-2 Spike Protein with Human Angiotensin-Converting Enzyme 2.
Verkhivker G
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33158276
[TBL] [Abstract][Full Text] [Related]
12. Molecular basis for drug repurposing to study the interface of the S protein in SARS-CoV-2 and human ACE2 through docking, characterization, and molecular dynamics for natural drug candidates.
Alazmi M; Motwalli O
J Mol Model; 2020 Nov; 26(12):338. PubMed ID: 33175236
[TBL] [Abstract][Full Text] [Related]
13. Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites.
Qiao B; Olvera de la Cruz M
ACS Nano; 2020 Aug; 14(8):10616-10623. PubMed ID: 32806067
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin-converting enzyme 2 (ACE2) receptor and SARS-CoV-2: Potential therapeutic targeting.
Sharifkashani S; Bafrani MA; Khaboushan AS; Pirzadeh M; Kheirandish A; Yavarpour Bali H; Hessami A; Saghazadeh A; Rezaei N
Eur J Pharmacol; 2020 Oct; 884():173455. PubMed ID: 32745604
[TBL] [Abstract][Full Text] [Related]
15. Structure-based drug designing and immunoinformatics approach for SARS-CoV-2.
Panda PK; Arul MN; Patel P; Verma SK; Luo W; Rubahn HG; Mishra YK; Suar M; Ahuja R
Sci Adv; 2020 Jul; 6(28):eabb8097. PubMed ID: 32691011
[TBL] [Abstract][Full Text] [Related]
16. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
[TBL] [Abstract][Full Text] [Related]
17. Hot spot profiles of SARS-CoV-2 and human ACE2 receptor protein protein interaction obtained by density functional tight binding fragment molecular orbital method.
Lim H; Baek A; Kim J; Kim MS; Liu J; Nam KY; Yoon J; No KT
Sci Rep; 2020 Oct; 10(1):16862. PubMed ID: 33033344
[TBL] [Abstract][Full Text] [Related]
18. Identification of a repurposed drug as an inhibitor of Spike protein of human coronavirus SARS-CoV-2 by computational methods.
Unni S; Aouti S; Thiyagarajan S; Padmanabhan B
J Biosci; 2020; 45(1):. PubMed ID: 33184246
[TBL] [Abstract][Full Text] [Related]
19. Interaction of Human ACE2 to Membrane-Bound SARS-CoV-1 and SARS-CoV-2 S Glycoproteins.
Anand SP; Chen Y; Prévost J; Gasser R; Beaudoin-Bussières G; Abrams CF; Pazgier M; Finzi A
Viruses; 2020 Sep; 12(10):. PubMed ID: 33003587
[TBL] [Abstract][Full Text] [Related]
20. The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies.
Papageorgiou AC; Mohsin I
Cells; 2020 Oct; 9(11):. PubMed ID: 33105869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]